2023-01-012023-12-312023-12-31false12354283CITY CLINICS GROUP LIMITED2024-12-2486220falseiso4217:GBPxbrli:pure123542832023-01-01123542832023-12-31123542832023-01-012023-12-31123542832022-01-01123542832022-12-31123542832022-01-012022-12-3112354283bus:SmallEntities2023-01-012023-12-3112354283bus:AuditExempt-NoAccountantsReport2023-01-012023-12-3112354283bus:FullAccounts2023-01-012023-12-3112354283bus:PrivateLimitedCompanyLtd2023-01-012023-12-3112354283core:WithinOneYear2023-12-3112354283core:AfterOneYear2023-12-3112354283core:WithinOneYear2022-12-3112354283core:AfterOneYear2022-12-3112354283core:ShareCapital2023-12-3112354283core:SharePremium2023-12-3112354283core:RevaluationReserve2023-12-3112354283core:OtherReservesSubtotal2023-12-3112354283core:RetainedEarningsAccumulatedLosses2023-12-3112354283core:ShareCapital2022-12-3112354283core:SharePremium2022-12-3112354283core:RevaluationReserve2022-12-3112354283core:OtherReservesSubtotal2022-12-3112354283core:RetainedEarningsAccumulatedLosses2022-12-3112354283core:LandBuildings2023-12-3112354283core:PlantMachinery2023-12-3112354283core:Vehicles2023-12-3112354283core:FurnitureFittings2023-12-3112354283core:OfficeEquipment2023-12-3112354283core:NetGoodwill2023-12-3112354283core:IntangibleAssetsOtherThanGoodwill2023-12-3112354283core:ListedExchangeTraded2023-12-3112354283core:UnlistedNon-exchangeTraded2023-12-3112354283core:LandBuildings2022-12-3112354283core:PlantMachinery2022-12-3112354283core:Vehicles2022-12-3112354283core:FurnitureFittings2022-12-3112354283core:OfficeEquipment2022-12-3112354283core:NetGoodwill2022-12-3112354283core:IntangibleAssetsOtherThanGoodwill2022-12-3112354283core:ListedExchangeTraded2022-12-3112354283core:UnlistedNon-exchangeTraded2022-12-3112354283core:LandBuildings2023-01-012023-12-3112354283core:PlantMachinery2023-01-012023-12-3112354283core:Vehicles2023-01-012023-12-3112354283core:FurnitureFittings2023-01-012023-12-3112354283core:OfficeEquipment2023-01-012023-12-3112354283core:NetGoodwill2023-01-012023-12-3112354283core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3112354283core:ListedExchangeTraded2023-01-012023-12-3112354283core:UnlistedNon-exchangeTraded2023-01-012023-12-3112354283core:MoreThanFiveYears2023-01-012023-12-3112354283core:Non-currentFinancialInstruments2023-12-3112354283core:Non-currentFinancialInstruments2022-12-3112354283dpl:CostSales2023-01-012023-12-3112354283dpl:DistributionCosts2023-01-012023-12-3112354283core:LandBuildings2023-01-012023-12-3112354283core:PlantMachinery2023-01-012023-12-3112354283core:Vehicles2023-01-012023-12-3112354283core:FurnitureFittings2023-01-012023-12-3112354283core:OfficeEquipment2023-01-012023-12-3112354283dpl:AdministrativeExpenses2023-01-012023-12-3112354283core:NetGoodwill2023-01-012023-12-3112354283core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3112354283dpl:GroupUndertakings2023-01-012023-12-3112354283dpl:ParticipatingInterests2023-01-012023-12-3112354283dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3112354283core:ListedExchangeTraded2023-01-012023-12-3112354283dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3112354283core:UnlistedNon-exchangeTraded2023-01-012023-12-3112354283dpl:CostSales2022-01-012022-12-3112354283dpl:DistributionCosts2022-01-012022-12-3112354283core:LandBuildings2022-01-012022-12-3112354283core:PlantMachinery2022-01-012022-12-3112354283core:Vehicles2022-01-012022-12-3112354283core:FurnitureFittings2022-01-012022-12-3112354283core:OfficeEquipment2022-01-012022-12-3112354283dpl:AdministrativeExpenses2022-01-012022-12-3112354283core:NetGoodwill2022-01-012022-12-3112354283core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3112354283dpl:GroupUndertakings2022-01-012022-12-3112354283dpl:ParticipatingInterests2022-01-012022-12-3112354283dpl:GroupUndertakingscore:ListedExchangeTraded2022-01-012022-12-3112354283core:ListedExchangeTraded2022-01-012022-12-3112354283dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-01-012022-12-3112354283core:UnlistedNon-exchangeTraded2022-01-012022-12-3112354283core:NetGoodwill2023-12-3112354283core:IntangibleAssetsOtherThanGoodwill2023-12-3112354283core:LandBuildings2023-12-3112354283core:PlantMachinery2023-12-3112354283core:Vehicles2023-12-3112354283core:FurnitureFittings2023-12-3112354283core:OfficeEquipment2023-12-3112354283core:AfterOneYear2023-12-3112354283core:WithinOneYear2023-12-3112354283core:ListedExchangeTraded2023-12-3112354283core:UnlistedNon-exchangeTraded2023-12-3112354283core:ShareCapital2023-12-3112354283core:SharePremium2023-12-3112354283core:RevaluationReserve2023-12-3112354283core:OtherReservesSubtotal2023-12-3112354283core:RetainedEarningsAccumulatedLosses2023-12-3112354283core:NetGoodwill2022-12-3112354283core:IntangibleAssetsOtherThanGoodwill2022-12-3112354283core:LandBuildings2022-12-3112354283core:PlantMachinery2022-12-3112354283core:Vehicles2022-12-3112354283core:FurnitureFittings2022-12-3112354283core:OfficeEquipment2022-12-3112354283core:AfterOneYear2022-12-3112354283core:WithinOneYear2022-12-3112354283core:ListedExchangeTraded2022-12-3112354283core:UnlistedNon-exchangeTraded2022-12-3112354283core:ShareCapital2022-12-3112354283core:SharePremium2022-12-3112354283core:RevaluationReserve2022-12-3112354283core:OtherReservesSubtotal2022-12-3112354283core:RetainedEarningsAccumulatedLosses2022-12-3112354283core:NetGoodwill2022-01-0112354283core:IntangibleAssetsOtherThanGoodwill2022-01-0112354283core:LandBuildings2022-01-0112354283core:PlantMachinery2022-01-0112354283core:Vehicles2022-01-0112354283core:FurnitureFittings2022-01-0112354283core:OfficeEquipment2022-01-0112354283core:AfterOneYear2022-01-0112354283core:WithinOneYear2022-01-0112354283core:ListedExchangeTraded2022-01-0112354283core:UnlistedNon-exchangeTraded2022-01-0112354283core:ShareCapital2022-01-0112354283core:SharePremium2022-01-0112354283core:RevaluationReserve2022-01-0112354283core:OtherReservesSubtotal2022-01-0112354283core:RetainedEarningsAccumulatedLosses2022-01-0112354283core:AfterOneYear2023-01-012023-12-3112354283core:WithinOneYear2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:CostValuation2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3112354283core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3112354283core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3112354283core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3112354283core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3112354283core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3112354283core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3112354283core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3112354283core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3112354283core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3112354283core:Non-currentFinancialInstrumentscore:CostValuation2022-12-3112354283core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-12-3112354283core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-12-3112354283core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-12-3112354283core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-12-3112354283core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-12-3112354283core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-12-3112354283core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-12-3112354283core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-12-3112354283bus:Director12023-01-012023-12-3112354283bus:Director22023-01-012023-12-3112354283core:FurnitureFittingsToolsEquipment2022-12-3112354283core:FurnitureFittingsToolsEquipment2023-01-012023-12-3112354283core:FurnitureFittingsToolsEquipment2023-12-31

CITY CLINICS GROUP LIMITED

Registered Number
12354283
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2023

CITY CLINICS GROUP LIMITED
Company Information
for the year from 1 January 2023 to 31 December 2023

Directors

JEYARATHNAM, Vishnu Shankar
MOHAMED, Mohamed Abdulrahman, Dr

Registered Address

82 Harley Street
London
W1G 7HN

Registered Number

12354283 (England and Wales)
CITY CLINICS GROUP LIMITED
Balance Sheet as at
31 December 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets3347,455109,848
347,455109,848
Current assets
Debtors158,206148,525
Cash at bank and on hand204,28461,113
362,490209,638
Creditors amounts falling due within one year4(873,679)(163,658)
Net current assets (liabilities)(511,189)45,980
Total assets less current liabilities(163,734)155,828
Creditors amounts falling due after one year5(141,278)(126,178)
Net assets(305,012)29,650
Capital and reserves
Called up share capital11
Profit and loss account(305,013)29,649
Shareholders' funds(305,012)29,650
The financial statements were approved and authorised for issue by the Board of Directors on 24 December 2024, and are signed on its behalf by:
JEYARATHNAM, Vishnu Shankar
Director
Registered Company No. 12354283
CITY CLINICS GROUP LIMITED
Notes to the Financial Statements
for the year ended 31 December 2023

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Land and buildings10
Plant and machinery5
Fixtures and fittings3
Office Equipment3
2.Average number of employees

20232022
Average number of employees during the year47
3.Tangible fixed assets

Land & buildings

Plant & machinery

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 January 23104,4745,9041,81612,414124,608
Additions-281,589--281,589
At 31 December 23104,474287,4931,81612,414406,197
Depreciation and impairment
At 01 January 232,5304,3568357,03914,760
Charge for year10,44729,4776053,45343,982
At 31 December 2312,97733,8331,44010,49258,742
Net book value
At 31 December 2391,497253,6603761,922347,455
At 31 December 22101,9441,5489815,375109,848
4.Creditors: amounts due within one year

2023

2022

££
Trade creditors / trade payables8,908-
Amounts owed to related parties5,063246
Taxation and social security-42,718
Other creditors859,708120,694
Total873,679163,658
5.Creditors: amounts due after one year

2023

2022

££
Other creditors141,278126,178
Total141,278126,178